Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region [Yahoo! Finance]
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $3.00 price target on the stock.
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.